Dr. Esteves is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3809 spring street
Racine, WI 53405Phone+1 262-687-5000Fax+1 262-687-5098
Education & Training
Oklahoma State University Center for Health SciencesClass of 2011
Certifications & Licensure
IL State License 2024 - 2026
AZ State License 2024 - 2025
CO State License 2020 - 2025
MT State License 2024 - 2025
ND State License 2021 - 2025
OK State License 2012 - 2025
TX State License 2024 - 2025- AOA Board of Internal Medicine Oncology
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsA Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal MalignanciesCorina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette M. Cotreau
Clinical Colorectal Cancer. 2015-03-01 - 313 citationsTivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III TrialRobert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy
Journal of Clinical Oncology. 2013-10-20 - 21 citationsPhase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Mayer Fishman, Sandy Srinivas, Ralph J. Hauke, Robert J. Amato, Brooke Esteves
European Journal of Cancer. 2013-09-01
Press Mentions
Who's News: Nov. 6November 5th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
